FLT3/ITD-mutated AML thus carries a poor prognosis and is placed in the intermediate to adverse risk category per European Leukemia Net (ELN)/National Comprehensive Cancer Network (NCCN) risk stratification (Dohner et al., 2017; Tallman et al., 2019). The gene discussed is FLT3; the disease is acute myeloid leukemia.